THE FUTURE
OF GENE THERAPY
Aletheia Neuroenergetics harnesses the power of gene therapy to augment neuroenergetics for the treatment of neurodegenerative diseases
VISION
We’re changing the approach to gene therapy
Aletheia is developing gene therapies based on neuroenergetics – improving the production of energy within the brain to augment energy demands and restore neural function
LEAD INDICATION
Aletheia is developing a gene therapy which augments neuronal energy demands to slow the progression of ALS & restore neural function
Why ALS
Amyotrophic Lateral Sclerosis (ALS) is caused by the relentless degeneration of motor neurons in the brain and spinal cord resulting in paralysis and death
​
Aletheia is developing a gene therapy which creates a novel metabolic pathway to significantly restore energy production and neural function
Neuroenergetics
In ALS, there is universal disruption of metabolism in diseased neurons leading to loss of energy production, which contributes to neuronal dysfunction & degeneration
​
The augmentation of neuroenergetics has utility for ALS as well as numerous other neurological disorders
Innovative Platform for CNS Diseases
Aletheia has the potential to leverage its leading technology platform to develop and commercialize products targeting other neurological disorders which require uninterrupted supply of energetic currency for metabolic homeostasis
